Detalhe da pesquisa
1.
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Ann Allergy Asthma Immunol
; 126(2): 187-193, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33169672
2.
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study.
Ann Allergy Asthma Immunol
; 126(5): 576-583.e4, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33333295
3.
Tezepelumab in Adults with Uncontrolled Asthma.
N Engl J Med
; 377(10): 936-946, 2017 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28877011
4.
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
J Allergy Clin Immunol
; 143(1): 135-141, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906525
5.
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
J Am Acad Dermatol
; 80(4): 1013-1021, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30550828
6.
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Gastroenterology
; 153(1): 77-86.e6, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28390867
7.
A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease.
Respir Res
; 18(1): 153, 2017 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28793896
8.
Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and ratesâ©.
Int J Clin Pharmacol Ther
; 55(7): 606-620, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28590244
9.
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
J Clin Pharmacol
; 61(7): 901-912, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368307
10.
Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab.
Int J Chron Obstruct Pulmon Dis
; 14: 1177-1185, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31239655
11.
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Lancet Respir Med
; 2(11): 891-901, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25208464
12.
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Lancet Respir Med
; 2(11): 879-890, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25306557
13.
Challenge models to assess new therapies in chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis
; 7: 597-605, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23055710